NEW YORK (GenomeWeb News) - RXi Pharmaceuticals has signed a three-year agreement with the University of Massachusetts Medical School that will allow the company to license all unrestricted therapeutic RNAi technology the school develops during that period, RXi parent company CytRx said today.
 
RXi said it licensed the UMMS technology for a combination of "cash and equity." Details of the financial terms were not provided.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.